Terms: = Breast cancer AND ERCC2, TTD, 2068, ENSG00000104884, COFS2, P18074, MGC102762, XPD, MGC126219, MGC126218, EM9 AND Clinical Outcome
4 results:
1. Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2- metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial.
Harbeck N; Fasching PA; Wuerstlein R; Degenhardt T; Lüftner D; Kates RE; Schumacher J; Räth P; Hoffmann O; Lorenz R; Decker T; Reinisch M; Göhler T; Staib P; Gluz O; Schinköthe T; Schmidt M;
Ann Oncol; 2023 Aug; 34(8):660-669. PubMed ID: 37201751
[TBL] [Abstract] [Full Text] [Related]
2. AGXT and ercc2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin.
Kjersem JB; Thomsen M; Guren T; Hamfjord J; Carlsson G; Gustavsson B; Ikdahl T; Indrebø G; Pfeiffer P; Lingjærde O; Tveit KM; Wettergren Y; Kure EH
Pharmacogenomics J; 2016 Jun; 16(3):272-9. PubMed ID: 26261061
[TBL] [Abstract] [Full Text] [Related]
3. Single nucleotide polymorphisms (SNPs) of ercc2, hOGG1, and XRCC1 DNA repair genes and the risk of triple-negative breast cancer in Polish women.
Smolarz B; Makowska M; Samulak D; Michalska MM; Mojs E; Wilczak M; Romanowicz H
Tumour Biol; 2014 Apr; 35(4):3495-502. PubMed ID: 24402573
[TBL] [Abstract] [Full Text] [Related]
4. Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study.
Schöffski P; Taron M; Jimeno J; Grosso F; Sanfilipio R; Casali PG; Le Cesne A; Jones RL; Blay JY; Poveda A; Maki RG; Nieto A; Tercero JC; Rosell R
Eur J Cancer; 2011 May; 47(7):1006-12. PubMed ID: 21376569
[TBL] [Abstract] [Full Text] [Related]
